Results 111 to 120 of about 6,454 (219)

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

Frontiers in Pharmacology
Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1 ...
Tayla A. Rees, Tayla A. Rees, Tayla A. Rees, Benjamin J. Buttle, Zoe Tasma, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Paul W. R. Harris, Paul W. R. Harris, Christopher S. Walker, Christopher S. Walker   +11 more
doaj   +1 more source

Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports [PDF]

Aims: Suicide is a global public health concern, accounting for nearly 700,000 deaths annually. Although well-established risk factors, including mental health disorders, are widely recognized, emerging concerns have surfaced regarding a potential ...
Baldini, Valentina, Di Stefano, Ramona, Jannini, Emmanuele A., Pacitti, Francesca, Rindi, Lorenzo V., Rossi, Alessandro, Rossi, Rodolfo   +6 more
core   +1 more source

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1683-1692, March 2026.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti, Matt Capehorn, Esther Artime, Lill‐Brith von Arx, Alun L. Davies, Atif Adam, Anastasia Lampropoulou   +6 more
wiley   +1 more source

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies

Endocrinology, Diabetes & Metabolism
Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects.
Jimmy Wen, Burhaan Syed, Denise Nadora, Christiane How‐Volkman, Ethan Bernstein, Alina Truong, Muzammil Akhtar, Adam Razick, Jose Puglisi, Eldo Frezza   +9 more
doaj   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1622-1637, March 2026.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Obesity & Metabolic Syndrome
Background : Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)-glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of various metabolic disorders.
Muhammad Umar Mahar, Omar Mahmud, Salaar Ahmed, Saleha Ahmed Qureshi, Wasila Gul Kakar, Syeda Sadia Fatima   +5 more
doaj   +1 more source

Recent Developments in Tirzepatide\u27s Role in Reducing Cardiovascular Disease Risk Factors in Adults with Type 2 Diabetes [PDF]

Objective: This literature review aims to investigate recent developments in tirzepatide’s ability to lessen CVD risk factors for adults with increased risk of major adverse cardiovascular events. Background: Tirzepatide is an FDA - approved medication
Bryan, Carina, Jones, Talaya, Kahook, Zaneh, Parmar, Mayur   +3 more
core   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2403-2415, March 2026.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Evaluating Dose Titration in Semaglutide and Tirzepatide for Weight Loss: A Retrospective Academic Call Center Study

Obesities
Obesity affects approximately 40% of U.S. adults and is associated with increased cardiometabolic risk. While lifestyle interventions remain fundamental, pharmacologic therapies such as Semaglutide and tirzepatide have demonstrated significant weight ...
Goar Alvarez, Lianette Veliz, Stephanie Michaels, David Pino, Jun Wu   +4 more
doaj   +1 more source

Exploring the role of gastrointestinal brake mechanisms in the management of obesity with focus on bariatric surgery [PDF]

This thesis examined gut hormone secretion, gastric emptying, small bowel transit, gut barrier function, and gut bacteria in obesity and after weight loss surgery.
Wilbrink, Jennifer Amely
core   +1 more source